| This week's sponsor is Premier Research. | |  | Rare Cancer Drug Research: What to Know Going In
Rare cancer drug research requires oncology and rare disease expertise and careful attention to trial design and regulatory demands. Get started with our white paper. Premier Research. It's what we do. Best. |
Today's Rundown Featured Story | | | Wednesday, June 13, 2018 A top Celgene executive has pinned the blame for the botched ozanimod filing on Receptos. Nadim Ahmed said Celgene’s arm’s-length relationship with the biotech it bought for $7.2 billion three years ago led to a substandard filing and embarrassing refusal-to-file notice. |
|
|
| This week's sponsor is Catalent. | |  | |
Top Stories Wednesday, June 13, 2018 VTv's azeliragon missed its coprimary endpoints in a phase 3 trial in mild Alzheimer's disease. The data mirror those of an identical study that read out in April. Wednesday, June 13, 2018 Flex Pharma must go back to the drawing board on its lead candidate, but it can't afford to do so, leaving it to scrap a pair of midstage trials, cut 60% of its workforce and consider options like a sale or merger to keep afloat. Wednesday, June 13, 2018 During the BIO International Convention in Boston last week, an unaffiliated party featured topless dancers and models painted with the logos of investment firms and biotech companies sponsoring the event, incensing the chairman of the trade group to the point of reconsidering their memberships in the organization. Tuesday, June 12, 2018 ResTORbio has brought on Novartis cardiology researcher Kerry Russell to serve in the newly created role of VP of clinical development as the company aims to expand its pipeline in aging-related diseases. Tuesday, June 12, 2018 Stryker has made a quiet offer to acquire its rival, Boston Scientific, which would create a behemoth with $21.5 billion in annual sales through one of the largest medical device deals on record, according to a report from the Wall Street Journal. | This week's sponsor is cobra:bio. | |  | Accelerating Protein Production Since 1995
Cobra’s maxXpress service uses UCOE technology enables rapid production of monoclonal antibodies (mAbs), recombinant proteins and biosimilars while ensuring efficient, stable expression. More... |
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Presented by: CMK Select It’s time. Your product launch is coming. Are you prepared to go face-to-face with the marketplace? Learn how to create a foundation for success, drawing upon our experience with more than 65 launches. Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. | 
